This week in psychedelic business news: Mindset Pharma files another patent for compounds with “perfect microdosing drug profile,” and Core One Labs is preparing to capitalize on functional mushroom market.
CEO James Lanthier compares psychedelic medicines to aspirin, and explains why the company’s lead candidate may be better than psilocybin.
In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.
This week in psychedelic business news: two patents may revolutionize the medical application of psychedelic compounds; DMT and ibogaine clinical trials show promise; and stock news for psychedelic investors.
This week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class research and drug development facility, and Awakn Life Sciences buys up ketamine clinics across the Nordics.
This week in psychedelic business news: major DMT development for stroke treatment; a propriety psilocybin formulation has potential to treat obesity; two more companies join the OTC Pink Market.
“Magic Truffle” producer and distributor Red Light Holland has had a very busy week, and Filament Health files a “milestone” patent.
“The data suggests that we have a new drug that may be at least as effective, if not more effective, than 5-MeO-DMT and, more importantly, it looks like it is much safer,” says Mindset Pharma CEO James Lanthier.
Another clinic gets approval to conduct MDMA research, and new psychedelic research facilities open in Australia and the U.S., plus two game-changing psilocybin patents.
“Based on our research, we think we’re able to get to psilocybin in fewer steps than any of the other published methods,” says the company’s CEO.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.